Myriad Genetics (MYGN) PT Lowered to $4 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq set for sharp drop as Amazon, Intel amplify AI spending worries
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $6.48 -2.85%
Rating Summary:
6 Buy, 20 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 43 | New: 8
Rating Summary:
6 Buy, 20 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 43 | New: 8
Join SI Premium – FREE
TD Cowen analyst Kyle Boucher lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $4.00 (from $6.00) while maintaining a Hold rating.
You May Also Be Interested In
- Schneider National (SNDR) PT Lowered to $30 at UBS Following Mixed Q3 Results
- Stryker (SYK) PT Lowered to $290 at TD Cowen
- Canada Packers Inc (CPKR:CN) PT Lowered to Cdn$14 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
